B1962
Phase 2Small molecule
B1962 is one of 65 small molecule programs targeting Colorectal Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
254 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tecentriq
RochePhase 3
Decadron
AAspen Global Incorporated
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Acetylsalicylic Acid
BayerPhase 3
Balstilimab
AAgenus Inc.
Phase 3
XL092
RochePhase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
Trodelvy
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors1 trial
Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for B1962. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details